Phaseline

Companies › Fujian Mindong Rejuvenation Pharmaceutical

Fujian Mindong Rejuvenation Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Immunology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rupatifen Fumarate Capsules
H1-receptor antagonist (antihistamine)
–Phase 3Seasonal Allergic RhinitisOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07711262Rupatifen Fumarate CapsulesPhase 3Seasonal Allergic RhinitisImmunologyOct 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Pharvaris Netherlands AUG Therapeutics Lynk Pharmaceuticals Jiangsu Genscend Biopharmaceutical TRB Chemedica

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.